DR. REDDY'S LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,780 INR | -0.34% |
|
-2.18% | -0.31% |
| May. 21 | Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading | MT |
| May. 21 | Alvotech and Dr. Reddy's Partner to Commercialize Biosimilar Candidate Denosumab | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 | 280B 3.36B | Sales 2025 * | 300B 3.61B | Capitalization | 963B 11.56B |
|---|---|---|---|---|---|
| Net income 2024 | 55.78B 670M | Net income 2025 * | 55.26B 664M | EV / Sales 2024 | 3.43 x |
| Net cash position 2024 | 64.59B 776M | Net cash position 2025 * | 90.85B 1.09B | EV / Sales 2025 * | 2.9 x |
| P/E ratio 2024 |
18.4
x | P/E ratio 2025 * |
17.2
x | Employees | 25,863 |
| Yield 2024 |
0.65% | Yield 2025 * |
0.78% | Free-Float | 70.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Dr. Reddy's Laboratories Limited
More recommendations
More press releases
More news
| 1 day | -0.55% | ||
| 1 week | -2.18% | ||
| Current month | -6.84% | ||
| 1 month | -2.74% | ||
| 3 months | -9.35% | ||
| 6 months | +3.13% | ||
| Current year | -0.31% |
1 week
5 709.00
5 966.95
1 month
5 709.006 419.90
Current year
5 520.656 505.90
1 year
4 384.256 505.90
3 years
3 654.006 505.90
5 years
2 351.206 505.90
10 years
1 872.956 505.90
| Managers | Title | Age | Since |
|---|---|---|---|
Erez Israeli
CEO | Chief Executive Officer | 57 | 18-04-01 |
Parag Agarwal
DFI | Director of Finance/CFO | - | 20-11-01 |
| Chairman | 56 | 93-01-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gunupati Prasad
CHM | Chairman | 63 | 86-04-07 |
| Chairman | 56 | 93-01-17 | |
Kalpana Morparia
BRD | Director/Board Member | 74 | 07-06-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 5,780 | -0.55% | 491,373 |
| 24-05-18 | 5,812 | +0.21% | 22,645 |
| 24-05-17 | 5,800 | -0.87% | 601,339 |
| 24-05-16 | 5,850 | -0.42% | 732,097 |
| 24-05-15 | 5,875 | +0.11% | 291,681 |
Delayed Quote NSE India S.E., May 21, 2024 at 07:40 am EDT
More quotes
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows:
- sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines;
- sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services;
- other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc.
Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Sector
Pharmaceuticals
Calendar
08:30pm
- Investor Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
5,781
INR
Average target price
6,101
INR
Spread / Average Target
+5.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.78% | 705B | |
| +32.82% | 583B | |
| -3.51% | 364B | |
| +19.94% | 332B | |
| +5.14% | 291B | |
| +16.64% | 238B | |
| -4.13% | 210B | |
| +10.63% | 209B | |
| +9.32% | 169B |
- Stock Market
- Equities
- DRREDDY Stock
- DRREDDY Stock